Background. An abnormal signal-averaged ECG (SAECG) has predictive value for arrhythmic events in patients with coronary artery disease. The purpose of this study was to investigate whether an abnormal SAECG could provide prognostic information in patients with nonischemic dilated cardiomyopathy.
Results

Clinical Characteristics
The clinical characteristics of the 114 patients are outlined in Table 1 and Figure 1 . Drug therapy and ECG characteristics are listed in Table 2 . No statistically significant differences among the three groups were observed in regard to peak Vo2, ejection fraction, pulmonary capillary wedge pressure, cardiac index, NYHA classification, age, sex, etiology of heart failure, or duration of follow-up ( Figure 1 ). Antiarrhythmic drug use was comparable between the three groups, although patients with bundle branch block had more implantable defibrillators (p<0.05) ( Figure 2 sudden death than did patients with a normal SAECG (p<0.01) ( Figure 3 ).
SAECG
Standard QRS duration, filtered QRS duration, and duration of root-mean-square 40 were greater in patients with an abnormal SAECG than in patients with a normal SAECG, whereas the root-mean-square of last 40 msec was reduced (Table 3) .
Of the 20 patients who had abnormal SAECG, 80% had filtered QRS duration >120 msec, 55% had rootmean-square 40 <20 puV, and 45% had duration <40
,gV of >38 msec. Nine of the patients had an abnormal SAECG by more than one criteria. Of the 66 patients with a normal SAECG, only eight patients had a filtered QRS duration that ranged from 115 to 120 msec. Representative examples of a normal and abnormal SAECG are shown in Figure 4 . 
Clinical Outcome
Clinical outcome is summarized in Table 4 . All deaths in the normal SAECG group were from heart failure. No patient in the group developed any significant arrhythmias prospectively. Three patients required urgent transplant.
In the patients with an abnormal SAECG, seven patients died. Five deaths were sudden, and two deaths resulted from progressive heart failure. Of the five sudden deaths, three patients died while asleep, and (6) ( 1 2) (5) (Figure 5 ).
Event-free survival with events defined as VT or death for the entire group was 81% at 1 year. The percent of patients at 1 year without significant events was 95% for patients with normal SAECG, 88% for patients with a bundle branch block, and 39% for patients with abnormal SAECG (p<0.0001 versus both groups) (Figure 6 ).
Analysis performed using urgent transplant defined as a death rather than a censored observation yielded a 1-year survival of 80%. With division of patients into the three groups, 1-year survival was 90%, 56%, and 82% for normal SAECG, abnormal SAECG, and bundle branch block groups, respectively (p<0.04). One-year event-free survival with events defined as VT, death, or urgent transplant for the entire group was 75%. With division of patients into three groups, 1-year event-free rates were 90%, 39%, and 75% (p<0.0005) for patients with normal SAECG, abnormal SAECG, or bundle branch block, respectively. With analysis performed using urgent transplant as an additional end point, the worst prognosis was consistently in patients with an abnormal SAECG, although this was not significantly different from patients with bundle branch block. Deletion of patients receiving type IA or III antiarrhythmic drugs did not alter the 1-year event-free rate, which remained 91%, 39%, and 74% for the normal SAECG, abnormal SAECG, and bundle branch block groups, respectively. When patients with past VT were excluded, the prospective 1-year event-free rate was 89%, 25%, and 89% for the respective groups.
Univariate and Multivariate Analyses
Univariate and multivariate analyses were performed using death, urgent of whom had an abnormal SAECG. Seven deaths occurred in the 11 months of follow-up, and five of these deaths were from heart failure. Although they concluded that the SAECG was not predictive of sudden death, the number of outcomes was too small to reach any firm conclusion. Moreover, their study was similar to the present study in that the greatest risk to patients with a nonischemic cardiomyopathy and normal SAECG was progressive heart failure. 27 Middlekauf et al studied 22 patients with a dilated cardiomyopathy in whom three patients had abnormal SAECG by criteria that required a filtered QRS duration > 120 msec, plus either a root-mean-square voltage <20 piV or low-amplitude signal duration >40 msec. Patients with bundle branch block were not analyzed separately. Five sudden deaths occurred. The average filtered QRS duration and root-mean-square for these patients are not reported. Analysis was performed using data derived from patients with coronary artery disease as well as with nonischemic cardiomyopathy. 3 In our study, we also describe a significantly higher incidence of past ventricular arrhythmias in patients with an abnormal SAECG compared with patients with a normal SAECG. These findings confirm our previous Slowed ventricular activation manifested by a prolonged filtered QRS duration and presence of low-level late potentials appears to be a critical component of the arrhythmogenesis rather than a reflection of the severity of the disease. In our study, patients with an abnormal SAECG were comparable to patients with a normal SAECG in regard to left ventricular ejection fraction, peak exercise oxygen consumption, resting hemodynamic measurements, and NYHA functional classification. Thus, all parameters used to grade the severity of myocardial dysfunction were similar.
The presence of bundle branch block in our study was associated with more frequent past and prospective episodes of ventricular arrhythmias. In this study, all patients with bundle branch block who prospectively had VT had left bundle branch block. Two of the four who required urgent transplant had a left bundle branch block. Prior studies have reported bundle branch block to be an independent poor prognostic factor for patients with dilated cardiomyopathy.29,30 It has been hypothesized that presence of bundle branch block infers a diffuse degenerative disease of the myocardium and thus more extensive disease. Alternatively, it may simply imply damage to the His-Purkinje system because parameters used to measure disease severity (i.e., ejection fraction, resting hemodynamic measurements, and exercise capacity) were comparable in patients with bundle branch block and those with normal SAECG. Although in this study we presume that sudden death results from ventricular arrhythmia, prior studies suggest that the mechanisms for sudden death in patients with heart failure are diverse, with 53% of patients actually succumbing to bradyarrhythmic events and only 38% to ventricular arrhythmias.31 Sudden deaths in our study occurred out of hospital with none of the patients undergoing autopsy. Therefore, we cannot exclude bradyarrhythmias, electromechanical dissociation, or fatal embolic events in these patients. However, the fact that we were able to prospectively identify patients who had VT suggests that the SAECG is more than just a marker for diffuse myocardial disease. The mortality rate in our study appears surprisingly low with a 1-year mortality of 13%. Mortality rates for patients with dilated cardiomyopathy have ranged from 11% to 48%.3-5,30o32-36 In 1983, Franciosa et a13 reported a 1-year mortality of 23% for patients with dilated cardiomyopathy. The majority of these patients were not receiving vasodilator therapy, which has recently been shown to significantly prolong survival in patients with heart failure.32,38 Cardiac transplantation also was not widely available at the time of that report. Analysis performed using urgent transplant as an end point in our study raises the 1-year mortality to 20%. Thus, the improvement in our survival may be accounted for by the recent advances in the therapy of heart failure. Similar to Franciosa et al, Likoff-Jessup et a135 also reported better survival in patients with dilated cardiomyopathy than in patients with coronary artery disease. Thus, our excellent survival is not inconsistent with past reports.
The incidence of sudden death in our study also was low, with only five sudden deaths in the 114-patient cohort. The incidence of sudden death in patients with dilated cardiomyopathy in past reports has ranged from 4% to 88%.3-5 33,35-39Our experience is similar to that of Maskin et al,39 who described a 4% incidence of sudden death despite 71% incidence of nonsustained VT on Holter monitoring. Frequent monitoring of electrolyte and digoxin levels may have helped to decrease the incidence of sudden death in our population. Moreover, 100 of our patients had angiographically normal coronary arteries, and ischemia was unlikely to contribute to arrhythmias in our patients. In some of the prior studies, coronary anatomy was not as well defined, and in some studies patients with coexistent coronary artery disease were included. Widespread use of angiotensin converting enzyme inhibitors40 and treatment of only symptomatic arrhythmias may also have helped to limit our incidence of sudden death. 41 Results of the multivariate analysis demonstrate that an abnormal SAECG is an independent predictor of death in patients with dilated cardiomyopathy. This is the first study to demonstrate this finding. NYHA classification also was found to be an independent variable confirming earlier reports.33035 Surprisingly, neither left ventricular ejection fraction nor peak exercise oxygen consumption, the two variables that best quantitate the central and peripheral components of heart failure, were found to be independent predictors. Univariate analysis did demonstrate significance for peak Vo2. Moreover, both of these variables were significantly lower in patients who had an adverse event defined as death, VT, and/or urgent transplant.
Study Limitations
The study is limited in that a complete electrophysiological evaluation was The problem of sudden death, the mechanisms that produce it, and the means to prevent it remain a critical area for future research. SAECG will provide a powerful noninvasive tool in future research efforts to risk stratify patients with heart failure.
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